Barclays lowered the firm’s price target on UnitedHealth (UNH) to $337 from $350 and keeps an Overweight rating on the shares as part of a Q2 earnings preview. The firm expects the company to reinstate 2025 earnings per share guidance in the $20-21 range, down 26% year-over-year. It reduced estimates ahead of the earnings report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth Stock (UNH) Sinks as DOJ Criminal Probe into Medicare Fraud Deepens
- Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
- Justice Department investigates UnitedHealth’s Medicare billing, WSJ says
- Pressure continues to mount on health insurers as costs rise, WSJ says
- Mixed options sentiment in UnitedHealth with shares down 1.59%